Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates

Oncology Research

Volumn 12, Issue 5, 2000, Pages 231-239

  Backus, H H J ^a   Pinedo, H M ^a   Wouters, D ^a   Kuiper, C M ^a   Jansen, G ^a   Van Groeningen, C J ^a   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

5 Fluorouracil; AG337; Apoptosis; Colon; DNA damage; Multitargeted antifolate

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DIHYDROFOLATE REDUCTASE; DNA; ENZYME INHIBITOR; FLUOROURACIL; FOLIC ACID ANTAGONIST; NOLATREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; QUINAZOLINE DERIVATIVE; RNA; THYMIDYLATE SYNTHASE; TRANSFERASE;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE; COLON TUMOR; DNA DAMAGE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FLOW CYTOMETRY; FLUOROMETRY; HUMAN; METABOLISM;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE; COLONIC NEOPLASMS; DNA DAMAGE; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLOW CYTOMETRY; FLUOROMETRY; FLUOROURACIL; FOLIC ACID ANTAGONISTS; HUMANS; HYDROXYMETHYL AND FORMYL TRANSFERASES; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; QUINAZOLINES; RNA, NEOPLASM; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 0034574983     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504001108747729     Document Type: Article

References (44)

1. Takemura, Y.; Jackman, A. L. Folate-based thymidylate synthase inhibitors in cancer chemotherapy. Cancer Drugs 8:3-16; 1997.
2. Peters, G. J.; Ackland, S. P. New antimetabolites in preclinical and clinical development. Exp. Opin. Invest. Drugs 5:637-679; 1996.
3. Danenberg, P. V.; Malli, H.; Swenson, S. Thymidylate synthase inhibitors. Semin. Oncol. 26:621-631; 1999.
4. Moertel, C. G. Chemotherapy of gastrointestinal cancer. N. Engl. J. Med. 330:1136-1142; 1994.
5. Schmoll, H. J.; Büchele, T.; Grothey, A.; Dempke, W. Where do we stand with 5-fluorouracil? Semin. Oncol. 26:589-605; 1999.
6. Peters, G. J.; Noordhuis, P.; Komissarov, A.; Holwerda, U.; Kok, M.; Van Laar, J. A.; Van der Wilt, C. L.; Van Groeningen, V.; Pinedo, H. M. Quantification of 5-fluorouracil incorporation into RNA of human and murine tumors as measured with a sensitive gas chromatography-mass spectrometry assay. Anal. Biochem. 231:157-163; 1995.
7. Lönn, U.; Lönn, S. Increased growth inhibition and DNA lesions in human colon adenocarcinoma cells treated with methotrexate and 5-fluorodeoxy-uridine followed by calmodulin inhibitors. Cancer Res. 48:3319-3323; 1998.
8. Webber, S.; Bartlett, C. A.; Boritzki, T. J.; Hillard, J. A.; Howland, E. F.; Johnston, A. L.; Kosa, M.; Margosiak, S. A.; Morse, C. A.; Shetty, B. V. AG337, a novel lipophilic thymidylate synthase inhibitor: In vitro and in vivo pre-clinical studies. Cancer Chemother. Pharmacol. 37:509-517; 1996.
9. Jackman, A. L.; Taylor, G. A.; Gibson, W.; Kimbell, R.; Brown, M.; Calvert, A. H.; Judson, I. R.; Hughes, L. R. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study. Cancer Res. 51:5579-5586; 1991.
10. Shin, C.; Chen, V. J.; Gossett, L. S.; Gates, S. B.; MacKellar, W. C.; Habeck, L. L.; Shackelford, K. A.; Mendelsohn, L. G.; Soose, D. J.; Patel, V. F.; Andis, S. L.; Bewley, J. R.; Rayl, E. A.; Moroson, B. A.; Beardsley, G. P.; Kohler, W.; Ratnam, M.; Schultz, R. M. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 57:1116-1123, 1997.
11. Rusthoven, J. J.; Eisenhauer, E.; Buts, C.; Gregg, R.; Dancey, J.; Fisher, B. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. J. Clin. Oncol. 17:1194-1199; 1999.
12. Rafi, I.; Boddy, A. V.; Calvete, J. A.; Taylor, G. A.; Newell, D. R.; Bailey, N. P.; Lind, M. J.; Green, M.; Hines, J.; Johnstone, A.; Clendeninn, N.; Calvert, A. H. Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors. J. Clin. Oncol. 16:1331-1141; 1998.
13. Cocconi, G.; Cunningham, D.; Van Cutsem, E.; Francois, E.; Gustavsson, B.; van Hazel, G.; Kerr, D.; Possinger, K.; Hietschold, S. M. Open, randomised, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J. Clin. Oncol. 16:2943-2952; 1998.
14. Curtin, N. J.; Harris, A. L.; Aherne, G. W. Mechanism of cell death following thymidylate synthase inhibition: 2′-deoxyuridine-5′-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res. 51:2346-2352; 1991.
15. Matsui, S. I.; Arredondo, M. A.; Wrzosek, C.; Rustum, Y. M. DNA damage and p53 induction, do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells. Cancer Res. 56: 4715-4723; 1996.
16. Van der Wilt, C. L.; Kuiper, C. M.; Peters, G. J. Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines. Oncol. Res. 11:383-391; 1999.
17. Yin, M. B.; Voigt, W.; Panadero, A.; Vanhoefer, U.; Frank, C.; Pajovic, S.; Azizkhan, J.; Rustum, Y. M. P53 and WAF1 are induced and Rb protein is hypophosphorylated during cell growth inhibition by the thymidylate synthase inhibitor ZD1694 (Tomudex). Mol. Pharmacol. 51:630-636; 1997.
18. Tonkinson, J. L.; Marder, P.; Andis, S. L.; Schultz, R. M.; Gossett, L. S.; Shih, C.; Mendelsohn, L. G. Cell cycle effects of antifolate antimetabolites: Implications for cytotoxicity and cytostasis. Cancer Chemother. Pharmacol. 39:521-531; 1997.
19. Nita, M. E.; Nagawa, H.; Tominaga, O.; Tsuno, N.; Fujii, S.; Sasaki, S.; Fu, C. G.; Takenoue, T.; Tsuruo, T.; Muto, T. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of bcl-2 family proteins. Br. J. Cancer 78:986-992; 1998.
20. Peters, G. J.; Van Triest, B.; Backus, H. H. J.; Kuiper, C. M.; van der Wilt, C. L.; Pinedo, H. M. Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor Ralitrexed. Eur. J. Cancer 36:916-924; 2000.
21. Osaki, M.; Tatebe, S.; Goto, A.; Hayashi, H.; Oshimura, M.; Ito, H. 5-Fluorouracil (5-FU) induced apoptosis in gastric cancer cell lines - role of the p53 gene. Apoptosis 2:221-226; 1997.
22. Ju, J. F.; Banerjee, D.; Lenz, H. J.; Danenberg, K. D.; Schmittgen, T. C.; Spears, C. P.; Schonthal, A. H.; Manno, D. J.; Hochhauser, D.; Bertino, J. R.; Danenberg, P. V. Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity. Clin. Cancer Res. 4:1315-1322; 1998.
23. Miyashita, T.; Krajewski, M.; Krajewska, M.; Wang, H. G.; Lin, H. K.; Liebermann, D. A.; Hoffman, B.; Reed, J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805; 1994.
24. Kerr, J. F. R.; Winterford, C. M.; Harmon, B. V. Morphological criteria for identifying apoptosis. In: Celis, J. E., ed. Cell biology. A laboratory handbook. New York: Academic Press; 1994:319-329.
25. Kroemer, G. The proto-oncogene bcl-2 and its role in regulating apoptosis. Nat. Med. 3:614-620; 1997.
26. Keepers, Y. P. A. M.; Pizao, P. E.; Peters, G. J.; Van Ark-Otte, J.; Winograd, B. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur. J. Cancer 27:897-900; 1991.
27. Peters, G. J.; Smitskamp-Wilms, E.; Smid, K.; Pinedo, H. M.; Jansen, G. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions. Cancer Res. 59:5529-5535; 1999.
28. Peters, G. J.; van Dijk, J.; Laurensse, E.; van Groeningen, C. J.; Lankelma, J.; Leyva, A.; Nadal, J. C.; Pinedo, H. M. In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil. Br. J. Cancer 67:259-265; 1988.
29. Ferreira, C. G.; Span, S. W.; Peters, G. J.; Kruyt, F. A. E.; Giaccone, G. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small-cell lung cancer cell line NCI-H460. Cancer Res. 60:7133-7144; 2000.
30. Pizao, P. E.; Lyaruu, D. M.; Peters, G. J.; van Ark-Otte, J.; Winograd, B.; Giaccone, G.; Pinedo, H. M. Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates. Br. J. Cancer 66:660-665; 1992.
31. Backus, H. H. J.; Pinedo, H. M.; Wouters, D.; Padron, J. M.; Molders, N.; van der Wilt, C. L.; van Groeningen, C. J.; Jansen, G.; Peters, G. J. Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates. Int. J. Cancer 87: 771-778; 2000.
32. Peters, G. J.; Wets, M.; Keepers, Y. P. A. M.; Oskam, R.; van Ark-Otte, J.; Noordhuis, P.; Smid, K.; Pinedo, H. M. Transformation of mouse fibroblasts with the oncogenes H-ras or trk is associated with pronounced changes in drug sensitivity and metabolism. Int. J. Cancer 54:450-455; 1993.
33. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, U.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anti cancer-drug screening. J. Natl. Cancer Inst. 82:1107-1112; 1992.
34. Van der Wilt, C. L.; Smid, K.; Aherne, G. W.; Noordhuis, P.; Peters, G. J. Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells. Eur. J. Cancer 33: 471-478; 1997.
35. Birnboim, H. C.; Jecvak, J. J. Fluorometric method for rapid detection of DNA strand breaks in human white blood cells produced by low doses of radiation. Cancer Res. 41:1889-1892; 1981.
36. Tolis, C.; Peters, G. J.; Ferreira, C. G.; Pinedo, H. M.; Giaccone, G. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur. J. Cancer 35: 796-807; 1999.
37. Van Triest, B.; Pinedo, H. M.; Van Hensbergen, Y.; Smid, K.; Telleman, F.; Schoenmakers, P. S.; van der Wilt, C. L.; van Laar, J. A.; Noordhuis, P.; Jansen, G.; Peters, G. J. Thymidylate synthose levels as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 non-selected colon cancer cell lines. Clin. Cancer Res. 5:643-654; 1999.
38. Goshal, K.; Jacob, S. T. Specific inhibition of pre-ribosomal RNA processing in extracts from the lymphosarcoma cells treated with 5-fluorouracil. Cancer Res. 54:632-636; 1994.
39. Lane, D. P. P53, guardian of the genome. Nature 358:15-16; 1992.
40. Wadler, S.; Horowitz, R.; Zhang, H. Y.; Schwartz, E. L. Effects of pertubations of pools of deoxynucleoside triphosphates on expression of ribonucleotide reductase, a G1/S transition state enzyme, in p53-mutated cells. Biochem. Pharmacol. 55:1353-1360; 1998.
41. Van der Wilt, C. L.; Pinedo, H. M.; Smid, K.; Peters, G. J. Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res. 52:4922-4928; 1992.
42. Chu, E.; Allegra, C. J. The role of thymidylate synthase as an RNA binding protein. Bioessays 18:191-198; 1995.
43. Kitchens, M. E.; Forsthoefel, A. M.; Barbour, K. W.; Spencer, H. T.; Berger, F. G. Mechanisms of acquired resistance to thymidylate synthase inhibitors: The role of enzyme stability. Mol. Pharmacol. 56:1063-1070; 1999.
44. Yang, E.; Korsmeyer, S. J. Molecular thanatopsis: A discourse on the bcl-2 family and cell death. Blood 88:386-401; 1996.